Business Development

We know excellent science takes place all over the world, and we want to collaborate with the best and the brightest.

Buck’s Business Development group is here to identify ways to advance scientific discovery toward translation and, ultimately, potential therapeutic inventions and consumer products to benefit the public. By partnering with companies, managing material transfer, and incubating Buck startups, it is the BD team's mission and vision to provide easy access to breakthrough technologies with the end goal of helping everyone live better longer.




  • Remy Gross, III  Vice President, Business Development and Partnering

    As Vice President of Business Development at the Buck, Remy is actively engaged in new start-up formation and partnering deal flow. Remy took the Business Development office at the Buck from having no licenses/partnerships to licensing out over 80% of its patent portfolio and creating an average of two capitalized start-up companies per year from the novel science being performed at Buck. Remy brings in sponsored research for novel science in excess of 10M/year for the institute and done strategic licensing transactions with Astellas, Calico, Astera and many others. He has founded or represented parties in multiple venture and angel-backed companies. He has advised and helped create multiple new biopharmaceutical startups at Buck, such as Unity Biotechnology (UBX), Aeovian Therapeutics, BhB Therapeutics and multiple others. These and other companies have collectively raised over 300M to drive the creation of novel therapeutics and healthspan enhancers. A chemist by training, Remy was also instrumental in the building of Shearwater Corporation as its VP, Operations (sold to Inhale Therapeutic Systems, Inc. in 2001). Remy sits on the board of BhB Therapeutics, Napa Therapeutics and Selah Therapeutics. Remy acts as a strategic advisor to several therapeutic companies and sits on several boards including the gener8tor advisory board and several others. Most importantly, Remy is married with three children who are all launched and in grad school or working on the east coast. He enjoys fitness of any kind, reading and adding value wherever he can.

  • Ellen Kats, PhD  Senior Director, Business Development

    Ellen Kats joined the Buck with fifteen years of experience in business development, licensing, and alliance management. Previously, Ellen worked for UCSF’s Innovation Ventures, where she was responsible for sourcing and completing high value deals for the university’s most commercially attractive technologies, managed a large and diverse IP portfolio, advised faculty/staff on IP strategy, and negotiated intellectual property terms for large-scale strategic alliances with industry partners. Over the years, Ellen has completed a wide range of partnering deals and played critical roles in the formations of many start-ups which have gone on to have successful IPOs or acquisitions. Ellen is passionate about aiding Buck faculty and staff in realizing the fullest commercial potential in their inventions and aiding the Buck Institute to achieve its mission through strategic partnerships leading to successes in clinical and consumer product development and aging research. Ellen holds a PhD in Biomedical Science from UC San Diego, as well as a BA in Molecular and Cellular Biology with emphasis on Genetics from UC Berkeley. In her spare time, Ellen is an avid Opera fan and loves to read and write and travel the world, but especially to Italy and the Mediterranean. She also holds a black belt in Shorinji Kempo and at some point could speak and understand 4 other languages but is currently woefully out of practice.

  • Tanya Feldman  Senior IP and Contracts Manager

    Tanya Feldman brings to the Buck over twelve years of experience in patent prosecution operations, government award compliance, and procedure development. In her role as Senior IP and Contracts Manager, she oversees all aspects of maintaining Buck's IP portfolio, drafting and management of CDAs and MTAs, and various special projects. Prior to entering the field of academic tech transfer she tried her hand at a variety of opportunities in the culture and non-profit sectors, from serving as an assistant tour manager in South East Asia to helping launch a new museum in San Francisco. Regardless of the project or industry, she thrives on collaboration and believes there is always something new to be learned and shared.

  • Sharon Epstein, JD, PhD  Senior Director of Operations, Rejuvenome Project

    Sharon Epstein has been with the Buck for over 10 years now, advancing in her career from a post-doctoral research assistant to a Senior Director role in the Business Development group. Sharon first worked as an attorney in Brazil, her native country before deciding that a career in science was her passion. She then earned her Masters in Biology at the Weizmann Institute in Rehovot, Israel before completing her PhD at the University of Geneva (UNIGE) under Howard Riezman. She then went on to become a post-doctoral assistant in the laboratory of Pankaj Kapahi at the Buck Institute. Sharon has performed virtually all the functions within the technology transfer and industry contracts areas. Sharon is currently the Sr. Director of Rejuvenome Operations, focused on facilitating the operations of Rejuvenome, an Astera Institute initiative to fully understand mouse healthspan and lifespan in the context of aging and geroprotective interventions. In her free time, Sharon enjoys traveling and her dog Max.

  • Brianna Stubbs, PhD  Lead Translational Scientist

    Dr. Stubbs is a world expert in exogenous ketone metabolism and its implications for performance, resilience and health-span. She completed her PhD in Metabolic Physiology at the University of Oxford, studying the metabolism and the application of exogenous ketone salts and esters. Whilst completing her studies, she competed on the British International Rowing Team, and was a two-time World Champion lightweight athlete. Brianna is currently Lead Translational Scientist in the Business Development Team at The Buck Institute for Research on Aging where she is focused on the translation of ketone body research into consumer products and drugs that target healthy aging.

  • Rosalba Perrone, PhD  Lead Scientist

    Dr. Perrone joined the Verdin lab in January 2017. She earned her PhD in biomedicine at the University of Padua in Italy, studying innovative therapeutic targets at the HIV proviral level. In the Verdin lab, her main focus is to study the role of NAD+ metabolism and NAD+ consuming enzymes in aging and age-associated diseases. Rosalba is the Program Director for Napa Therapeutics, a company created by the Buck Institute and Juvenescence ltd. Napa Therapeutics is a discovery-stage company developing compounds focused on leveraging NAD+ metabolism to slow down the effects of aging and prevent and treat age-related disease. Science is not Rosalba’s only big passion. She loves to express herself through creative arts, from dancing to crochet. She loves everything that comes from her home country, Italy - especially the good food and music. Her first goal in life is to always be passionate, curious, and happy. Her motto is: “Resolve to be the sun!”


Whether through licensing, sponsored research or industry collaboration, we partner with companies to create relationships that work. It’s from these relationships that we hope to see continued progress in translating Buck discoveries and inventions into potential therapeutics and consumer products. We welcome the opportunity to speak with you about your ideas for partnering with us.

Material Transfer

Business Development is responsible for authorizing and approving material transfer in and out of the Buck. If you are interested in obtaining novel materials, you will need the consent of the relevant Buck principal investigator and you will have to complete our Material Transfer Agreement (MTA). Please complete our MTA intake form and e-mail it to Senior IP and Contracts Manager Tanya Feldman to work with you to complete your request in a timely manner.

Startup Incubator

We have all the necessary in-house expertise to help incubate Buck startups for our faculty and staff.  Our Business Development team will work with you to make sure all your incorporation documents are in order, lead financing discussions to get your NuCo funded, ensure all the IP is properly licensed, and provide space while your NuCo is getting off the ground.

From time to time, Buck can also make lab and office space available to partners and industry. The Buck’s unparalleled cores and facilities allow for industry partners to take advantage of access to not only our campus but also our seminar series and our scientists.

Income Distribution

The Buck Institute encourages translational research and entrepreneurship by sharing a substantive portion of its licensing revenue with the inventors and their laboratories.  The rest of the income will go into Buck’s general research fund to further our mission.  The pie chart on the left shows the breakdown of net revenues after required out-of-pocket expenses and 10% for Buck’s internal administrative costs are taken out of gross revenues.




Conflict of Interest policy (COI)

The COI Policy implements and ensures compliance with specific Federal requirements set forth by the United States Department of Health and Human Services, to strengthen accountability and transparency, promote Research objectivity and integrity, and ensure prudent stewardship of public funds.

IP Policy Manual

The Buck Institute’s Intellectual Property Policies and Procedures are developed to provide incentives for its researchers while protecting the integrity of their research, to protect the rights and aspirations of the Buck Institute and its sponsors, and to foster commercial development.

Support the Buck

We rely on donations to support the science that we believe will add years to people's lifespan and decades to their healthspan.